Profile data is unavailable for this security.
About the company
Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
- Revenue in USD (TTM)27.50m
- Net income in USD-169.55m
- Incorporated2021
- Employees483.00
- LocationExscientia PLCThe Schrodinger BuildingOxford Science ParkOXFORD OX4 4GEUnited KingdomGBR
- Phone+44 186 581 8941
- Websitehttps://www.exscientia.ai/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alumis Inc | 0.00 | -189.03m | 563.07m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Celcuity Inc | 0.00 | -82.59m | 565.45m | 55.00 | -- | 3.20 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Capricor Therapeutics Inc | 27.15m | -27.95m | 588.63m | 101.00 | -- | 50.30 | -- | 21.68 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Exscientia PLC (ADR) | 27.50m | -169.55m | 599.74m | 483.00 | -- | 1.52 | -- | 21.81 | -1.33 | -1.33 | 0.2164 | 3.05 | 0.042 | -- | 26.88 | 56,939.54 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 600.18m | 110.00 | -- | 2.46 | -- | 39.60 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 607.31m | 285.00 | -- | 2.53 | -- | 166.80 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
Entrada Therapeutics Inc | 239.40m | 104.44m | 615.28m | 168.00 | 5.59 | 1.43 | 5.70 | 2.57 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Savara Inc | 0.00 | -75.29m | 615.61m | 37.00 | -- | 5.08 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Neurogene Inc | 925.00k | -55.44m | 617.46m | 91.00 | -- | 3.98 | -- | 667.52 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 625.76m | 100.00 | -- | 6.56 | -- | 7.23 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
SS Innovations International Inc | 14.41m | -23.68m | 640.27m | 239.00 | -- | 37.70 | -- | 44.43 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 640.55m | 267.00 | 92.80 | -- | 69.47 | 1.60 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 645.50m | 180.00 | -- | 2.50 | -- | 3.94 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Annexon Inc | 0.00 | -115.16m | 648.72m | 71.00 | -- | 1.79 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 648.83m | 80.00 | -- | 2.86 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Laurion Capital Management LPas of 31 Mar 2024 | 5.41m | 4.28% |
Baillie Gifford & Co.as of 30 Jun 2024 | 4.40m | 3.48% |
Platinum Investment Management Ltd.as of 31 Mar 2024 | 3.95m | 3.13% |
Woodline Partners LPas of 31 Mar 2024 | 1.66m | 1.31% |
Bill & Melinda Gates Foundation Trust (Investment Management)as of 31 Mar 2024 | 1.59m | 1.26% |
MIC Capital Management UK LLPas of 31 Mar 2024 | 1.54m | 1.22% |
First Trust Advisors LPas of 31 Mar 2024 | 1.43m | 1.13% |
Irish Life Investment Managers Ltd.as of 04 Jul 2024 | 1.25m | 0.99% |
Marshall Wace LLPas of 31 Mar 2024 | 995.48k | 0.79% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 727.27k | 0.58% |